Caliway Reports the IND Acceptance of CBL-514 by the US FDA for the Treatment of Dercum's Disease
Shots:
- The US FDA has accepted the IND application of the company’s CBL-514 to conduct a P-II (CBL-0202DD) trial for the treatment of Dercum's Disease
- The P-II (CBL-0202DD) trial will investigate the efficacy, safety, and tolerance of CBL-514 vs PBO for treating Dercum's disease. Patient enrolment will begin in Q2’24
- The previous P-II (CBL-0201DD) study evaluating CBL-514 has shown its efficacy in reducing lipoma dimension by >50% and significantly improving pain by 4.7 points, indicating the potential to become the first approved treatment for Dercum's disease
Ref: Caliway | Image: Caliway
Related News:- Senti Bio Receives the US FDA’s Clearance on IND Application Submitted for SENTI-202 to Treat Hematologic Malignancies
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
